Prne
April 19th, 2009
SAN DIEGO - Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD
Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway.
AM211 is an oral, selective antagonist of the receptor DP2, which recent studies have shown to be a potential target for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The Phase I study is designed to obtain safety and proof of mechanism data for AM211.
“There remains a great deal of unmet medical need in asthma and COPD, and we look forward to exploring AM211’s potential as a new treatment option,” said Isabelle DeArmond, M.D., Vice President Clinical Development. “We may also explore AM211 in other inflammatory diseases based on the safety and proof of mechanism data from our Phase I studies.”
DP2 is also known as CRTH2 or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes. DP2 is a high affinity receptor for prostaglandin D2 and, in humans, is implicated in Th2-dependent allergic inflammation.
“The start of the AM211 clinical studies marks another impressive milestone in our company’s short existence. Our small but effective team has been able to bring three distinct molecules into the clinic in less than four years,” said Bob Baltera, Amira’s Chief Executive Officer. “We look forward to continuing this pace as we advance our next program for idiopathic pulmonary fibrosis toward the clinic.”
About Amira
Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease linked to the phospholipid pathways. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair(R). The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.
Source: Amira Pharmaceuticals, Inc.
Ian Stone of Russo Partners, +1-619-528-2220, ian.stone at russopartnersllc.com, for Amira Pharmaceuticals, Inc.
Filed under Biotechnology, Clinical Trials / Medical Discoveries, Health, Health Care / Hospitals, Pharmaceuticals | Tags: Amira Pharmaceuticals, california, denmark, Inc., San diego, Western Europe | Comment Below
Related Press Releases Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461August 17th, 2009 SAN DIEGO -
Amira Pharmaceuticals, Inc. announced today the submission of an Investigational New Drug application (IND) of AM461, its internally-discovered, oral drug candidate for the treatment and control of inflammatory and allergic disease linked to the arachidonic acid pathway, to the U.S. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 AuctionAugust 10th, 2009 WELLESLEY HILLS, Massachusetts -
Joseph F. Finn, Jr., C.P.A. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory DiseasesJune 29th, 2009 SAN DIEGO -
- Results Demonstrate Positive Proof of Mechanism
Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM211, the company's oral selective antagonist of the DP2 (also known as CRTH2) receptor. Living Cell Technologies' Diabetes Clinical Trial Authorized by New Zealand GovernmentJune 23rd, 2009 SYDNEY and AUCKLAND, New Zealand -
Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that the New Zealand Minister of Health, the Honourable Tony Ryall, has authorized LCT's New Zealand Phase I/IIa clinical trial of DIABECELL(R) for insulin dependent diabetes. The authorization confirms the conditions announced on 19 June 2009. ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)June 17th, 2009 SEATTLE, Washington, and LEIDEN, The Netherlands - ProFibrix B.V. today announced the start of the company's Phase II clinical trial for Fibrocaps(TM), the company's lead topical Hemostat product, with the successful treatment of the first patients for mild to moderate bleeding during liver surgery. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research ConferenceJune 14th, 2009 SAN DIEGO - Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke PatientsMay 5th, 2009 REHOVOT, Israel - D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients. D-Pharm plans to initiate the trial later this year following FDA review of the IND and SPA. Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry EyeApril 14th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its formulation of Cyclosporine. The results demonstrate statistically significant improvement with signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome. Vantia Therapeutics' Pipeline Continues to MatureMarch 23rd, 2009 SOUTHAMPTON, England - VA106483 Completes Phase IIa Trial and VA111913 Completes Phase I
Dosing
Vantia Therapeutics, a company focusing on first-in-class
therapies for unmet medical needs, announces further clinical trial progress
with its two lead development compounds, VA106483 for nocturia associated
with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea. The
Phase IIa trial of VA106483 has completed, while dosing is complete in the
Phase I trial of VA111913. BioCis Pharma Starts Phase IIa Trial in PsoriasisMarch 11th, 2009 TURKU, Finland - BioCis Pharma Ltd., a privately-held drug development company with its
headquarters in Turku, Finland, announced that it has begun a new Phase IIa
clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical
drug for dermatology. The double-blind, vehicle-controlled study is designed
to evaluate the tolerability, pharmacokinetics, and efficacy of the topical
product in a total of 18 subjects with mild to moderate plaque psoriasis.
Related News GVK Biosciences forms clinical research alliance with Excel PharmaStudiesApril 14th, 2009 HYDERABAD - GVK Biosciences (GVK BIO), Asia's leading integrated research services provider and Excel PharmaStudies (Excel), a leading Chinese Clinical Research Organization announced a strategic alliance to conduct clinical trials in Asia. The alliance provides clinical trial sponsors access to the scientific skills, talent pool, flexible resourcing, and cost-effectiveness of both India and China. Indian clinical research company to set-up unit in Kuala LumpurJuly 27th, 2009 NEW DELHI - The Ahmedabad-based Veeda Clinical Research organization is entering Malaysia's medical sector by setting up its advanced research unit at the Ampang Hospital in Kuala Lumpur by the year-end. India's fastest-growing clinical research organisation has selected the Ampang Hospital to conduct first phase clinical trials on humans under a quasi-commercial agreement with the Malaysian Health Ministry, The Star Online reports. Fast acting erectile disorder drug goes on trial againFebruary 15th, 2009 WASHINGTON - A new fast-acting oral drug for erectile dysfunction (ED) is ready for a crucial trial phase. It's going to be a multicentre, randomised, double-blind, placebo-controlled trial that will evaluate the safety and efficacy of Avanafil in the treatment of ED in men with type-1 or type-2 diabetes. MakroCare announces workshop on Advanced GCP on May 15May 6th, 2009 HYDERABAD - MakroCare, a global clinical services firm, provides clinical research support to pharmaceutical, biotechnology, and medical device industries, is taking a lead in the training of professionals for the clinical research industry by providing series of informational through workshop and seminars. Advanced GCP workshop will be held at CHITRAMAYEE Auditorium, State Arts Gallery, Kavuri Hills, Madhapur, Hyderabad on May 15. Trials testing safety of new antibody aimed at rabies virus launched in IndiaOctober 1st, 2009 WASHINGTON - A clinical trial testing the safety and activity of a human monoclonal antibody (MAB) developed to neutralize the rabies virus has been launched in King Edward Memorial Hospital in Mumbai, India. Serum Institute of India is working in a collaborative partnership with researchers from University of Massachusetts to manufacture and test the new antibody that would help treat people bitten by rabid animals. Developmental drug effective against radiation damageApril 23rd, 2009 WASHINGTON - A drug, currently under development, has been found effective in providing protection against damaging effects of radiation exposure. The research team from University of Pittsburgh School of Medicine has found that experimental drug JP4-039 protects cells from being damaged by radiation exposure. PM welcome in Kashmir if he initiates steps to solve state's problems: Umar FarooqSeptember 21st, 2009 SRINAGAR - The chairman of the moderate faction of the All Parties Hurriyat Conference, Mirwaiz Moulvi Muhammad Umar Farooq, said on Monday that he would welcome a visit to the state by Prime Minister Manmohan Singh to the Kashmir Valley if he initiates steps to resolve the long pending Kashmir issue. Addressing a gathering on the occasion of Eid, Farooq said: Today, I would like to welcome India's Prime Minister Manmohan Singh who is coming to Kashmir in some days if he announces some steps to solve the Kashmir problem. RAM Energy shares soar as analyst initiates coverage with "Market Outperform" ratingOctober 1st, 2009 RAM Energy shares soar as analyst initiates ratingNEW YORK — Shares of oil and gas company RAM Energy Resources Inc. soared on Thursday, as an analyst initiated coverage of the company with a "Market Outperform" rating. Contrave - Weight Loss Drug: How to participate in clinical trialJuly 21st, 2009 Contrave is an experimental weight-loss drug developed by Orexigen Therapeutics Inc. It has been shown to significantly aid weight loss
in three late-stage clinical trials. Trial runs for Delhi Metro's new train beginMay 22nd, 2009 NEW DELHI - Trial runs for the the newly procured broad gauge train that would ply on phase II of the Delhi Metro began here Friday. 'The trial run was carried out between 3 a.m.
|
|
